L. Guest

Real‐world effectiveness for 12 weeks of ledipasvir–sofosbuvir for genotype 1 hepatitis C: the Trio Health study

Elliot B. Tapper, Bruce R. Bacon, Michael P. Curry et al. · Journal of Viral Hepatitis · 2016 · 75 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real‐world cohort study

Elliot B. Tapper, Bruce R. Bacon, Michael P. Curry et al. · Hepatology · 2016 · 63 citations

Pharmacy, Clinical Pharmacy, Pharmacotherapy +14

Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients

Michael P. Curry, Elliot B. Tapper, Bruce R. Bacon et al. · Alimentary Pharmacology & Therapeutics · 2017 · 38 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/Sofosbuvir (LDV/SOF): Real World Data from 2034 Genotype 1 Patients in the Trio Network

Nezam H. Afdhal, B. Bacon, Michael P. Curry et al. · Journal of Hepatology · 2016 · 13 citations

Pharmacy, Pharmacotherapy, Molecular Virology +10